BMT Unit, Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah-Tiqva, Israel; Faculty of Medicine, Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Israel.
BMT Unit, Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah-Tiqva, Israel; Faculty of Medicine, Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Israel.
Leuk Res. 2014 Aug;38(8):913-7. doi: 10.1016/j.leukres.2014.05.020. Epub 2014 Jun 4.
We hypothesized that in patients with early post allogeneic transplantation toxicities, the omission of the 3rd dose of methotrexate with concomitant starting of MMF would favorably affect complications. We found a higher incidence of grade 2-4 acute GVHD in patients given two doses methotrexate and MMF (n=31) compared to those given three courses of methotrexate (n=70) (p=.004), while grade 3-4 was similar. Other transplantation outcomes, including overall regimen-related-toxicity, were comparable. We conclude that tailoring the GVHD prophylaxis regimen may decrease the early post transplantation complications, however this come at the extent of a higher incidence of non-severe acute GVHD.
我们假设，对于发生在同种异体移植后早期的毒性反应患者，省去第三剂甲氨蝶呤（MTX）并用霉酚酸酯（MMF）替代，可能有利于减少并发症。我们发现，接受两剂 MTX 和 MMF 治疗的患者（n=31）与接受三剂 MTX 治疗的患者（n=70）相比，发生 2-4 级急性移植物抗宿主病（GVHD）的比例更高（p=.004），但 3-4 级急性 GVHD 的发生率相似。其他移植结果，包括与方案相关的总体毒性，无差异。我们得出的结论是，调整 GVHD 预防方案可能会减少移植后早期的并发症，但这会导致非重度急性 GVHD 的发生率增加。
